Member Info for Bobbler

AF, the cat is out of the bag so to speak. Clearly doesn’t have a clue what he/she/them/ their is talking about. Very amateur disrupter.
Although I have to say sometimes slightly amusing, particularly when it throws its dummy out.

Potnak, I agree we shouldn’t whitewash over MHRA’s request. However I’m inclined to agree that it doesn’t have anything to do with the quality of the submission. The following statement was issued by the MHRA inspectorate, incidentally on the 8th Nov 2022, the same day that SAR released the RNS:

“ Throughout the pandemic we have taken a pragmatic approach to the 'expiry' of GMP Certificates, with these initially extended to the end of 2021 and then to the end of 2022. I can confirm that the 'expiry' of GMP certificates will again be extended until the end of 2023.8 Nov 2022”

I think it’s possible that due to the expiry of certification, MHRA may well have been requesting the review of data as a back stop. Just a thought.

Blob, who’s name calling now?
Clown.

Kool that’s great, you’ve let everyone know your concerns and intentions. Let’s move on.

Rebster, you are not wrong! Turncoat city.

Tim confirmed......
"Its a fantastic location for the 28p party, no Yacht access issues"

Your very welcome SOG.
Keep up the good research
Regards

SOG- that’s exactly what it is:
Share dilution is when a company issues additional stock, reducing the ownership proportion of a current shareholder. Shares can be diluted through a conversion by holders of optionable securities, secondary offerings to raise additional capital, or offering new shares in exchange for acquisitions or services.
And yes, it’s happened many times in the past decade.

Hope it’s not the case, but sadly I think it probably is him. RIP lover of whatsits and Toya Wilcox

This article might help some understand why it takes so long to develop potential molecules.
If a company the size of BMS with all its cash and resources takes years to progress candidates, it’s little wonder that a couple of guys in Cambridge might be behind.

https://www.bms.com/life-and-science/science/the-innovation-behind-tyk2-inhibition.html

Guessing that hit a nerve…….
Your narrative changes like the wind, very transparent.

Clown

This Kat can change its spots:

Koolkat01 Dec 2022 09:20
But the same can be said for you Sneck! Why are you and others so, so negative all the time? I'll tell you why..... because you and other negative posters are NOT invested here.

What a clown.

HBD, do you mean CoL or is it Jay from the “inbetweeners” they seem very similar

decided to transfer the clinical trial to Australia to progress the development of SDC-1801.

Data from clinical trials conducted in Australia is accepted by key jurisdictions, including the US Food and Drug Administration (FDA) and European Medicines Evaluation Agency (EMEA). This ensures research does not lose momentum. Clinical trials undertaken in Australia do not require US FDA Investigational New Drug (IND) application approval.

Australia’s world-leading clinical trials infrastructure, streamlined regulatory approval system, and grants and incentives attract both pharmaceutical giants and red-hot startups.

Sneckieboy, if you don’t believe what the board is saying then I would strongly suggest getting out. Once the trust has gone, then there’s nothing left, like a marriage really.

Sneckieboy, apologies if it was a confusing question. Clearly you are confident that it will come good, otherwise why would anyone stay invested.
Stick with it, history has shown there is a lot of money to be made with this share.

Sneckieboy, is it fair to assume you were also gullible enough to believe the board at the last meeting, or did you sell out? Just curious.

Sneckieboy please stop your constant ramping, this is never going to reach £1.50. You’re as bad as the share bashers……..